LX1032: Phase II start

This quarter, Lexicon will begin a double-blind, placebo-controlled, U.S. Phase II trial to evaluate oral LX1032 in about 28 patients. Lexicon licensed LX1032 to Symphony Icon in 2007 (see BioCentury,...